Reports

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Phosphodiesterase (PDE) Inhibitors Market: By Type: PDE4 Inhibitors, PDE5 Inhibitors, Others; By Route of Administration: Oral, Topical; By Application: Erectile Dysfunction, Chronic Obstructive Pulmonary Disease; Regional Analysis; Historical Market and Forecast (2017-2027); Competitive Landscape; Industry Events and Developments

Global Phosphodiesterase (PDE) Inhibitors Market Outlook

The global phosphodiesterase (PDE) inhibitors market is projected to grow at a CAGR of 5.4% during the forecast period of 2022-2027. The increasing prevalence of erectile dysfunction (ED) and the growing demand for targeted therapy, such as PDE5 inhibitors, are driving the growth of the phosphodiesterase (PDE) inhibitors industry globally.

 

Global Phosphodiesterase (PDE) Inhibitors Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Properties and Applications

A phosphodiesterase inhibitor belongs to a class of drugs inhibiting phosphodiesterase enzymes (PDEs), which normally break off phosphate groups, thus, preventing the growth of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in target cells.

 

Global Phosphodiesterase (PDE) Inhibitors Market by Administration

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The global phosphodiesterase (PDE) inhibitors industry can be broadly categorised based on its types, route of administration, applications, and regions.

  • Type:
    • PDE4 Inhibitors
    • PDE5 Inhibitors
    • Others
  • Route of Administration:
    • Oral
    • Tropical
    • Others
  • Application:
    • Erectile Dysfunction
    • Chronic Obstructive Pulmonary Disease
    • Others

The EMR report looks into the regional phosphodiesterase (PDE) inhibitors markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Phosphodiesterase (PDE) Inhibitors Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

Testosterone deficiency, prostate cancer, obesity, hypertension, hyperlipidemia, and intake of certain medicines, which could lead to erectile dysfunction, are the major factors for the industry growth. The high prevalence of these factors is leading to an increase in the incidences of erectile dysfunction (ED) conditions. The increased preference for PDE5 inhibitors, among other types, to treat ED and pulmonary hypertension is further aiding the industry growth. In addition, manufacturers are continuing to launch new PDE inhibitors with the advancement in technology, further expanding their therapeutic applications and increasing their sales. Region-wise, North America is expected to account for the largest share in the global industry over the forecast period owing to the increased penetration of the key players in the region.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global phosphodiesterase (PDE) inhibitors industry, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Vivus Inc.
  • Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Route of Administration, Application, Region
Breakup by Type PDE4 Inhibitors, PDE5 Inhibitors, Others
Breakup by Route of Administration Oral, Topical, Others
Breakup by Application Erectile Dysfunction, Chronic Obstructive Pulmonary Disease, Others
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Bayer AG, Eli Lilly and Co., Pfizer, Inc., Vivus, Inc., GlaxoSmithKline plc, Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Phosphodiesterase (PDE) Inhibitors Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Phosphodiesterase (PDE) Inhibitors Historical Market (2017-2021) 
    8.3    Global Phosphodiesterase (PDE) Inhibitors Market Forecast (2022-2027)
    8.4    Global Phosphodiesterase (PDE) Inhibitors Market by Type
        8.4.1    PDE4 Inhibitors
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    PDE5 Inhibitors
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Others
    8.5    Global Phosphodiesterase (PDE) Inhibitors Market by Route of Administration 
        8.5.1    Oral
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Topical
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Others
    8.6    Global Phosphodiesterase (PDE) Inhibitors Market by Application
        8.6.1    Erectile Dysfunction 
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2017-2021)
            8.6.1.3    Forecast Trend (2022-2027)
        8.6.2    Chronic Obstructive Pulmonary Disease
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2017-2021)
            8.6.2.3    Forecast Trend (2022-2027)
        8.6.3    Others
    8.7    Global Phosphodiesterase (PDE) Inhibitors Market by Region
        8.7.1    Market Share
            8.7.1.1    North America
            8.7.1.2    Europe
            8.7.1.3    Asia Pacific
            8.7.1.4    Latin America
            8.7.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Competitive Landscape
    11.1    Market Structure
    11.2    Company Profiles
        11.2.1    Bayer AG
            11.2.1.1    Company Overview
            11.2.1.2    Product Portfolio
            11.2.1.3    Demographic Reach and Achievements
            11.2.1.4    Certifications
        11.2.2    Eli Lilly and Co.
            11.2.2.1    Company Overview
            11.2.2.2    Product Portfolio
            11.2.2.3    Demographic Reach and Achievements
            11.2.2.4    Certifications
        11.2.3    Pfizer, Inc.
            11.2.3.1    Company Overview
            11.2.3.2    Product Portfolio
            11.2.3.3    Demographic Reach and Achievements
            11.2.3.4    Certifications
        11.2.4    Vivus, Inc.
            11.2.4.1    Company Overview
            11.2.4.2    Product Portfolio
            11.2.4.3    Demographic Reach and Achievements
            11.2.4.4    Certifications
        11.2.5    GlaxoSmithKline plc
            11.2.5.1    Company Overview
            11.2.5.2    Product Portfolio
            11.2.5.3    Demographic Reach and Achievements
            11.2.5.4    Certifications
        11.2.6    Others
12    Industry Events and Developments


List of Figures and Tables

1.    Global Phosphodiesterase (PDE) Inhibitors: Key Industry Highlights, 2016 and 2026
2.    Global Phosphodiesterase (PDE) Inhibitors Historical Market: Breakup by Type (USD Million), 2017-2021
3.    Global Phosphodiesterase (PDE) Inhibitors Market Forecast: Breakup by Type (USD Million), 2022-2027
4.    Global Phosphodiesterase (PDE) Inhibitors Historical Market: Breakup by Route of Administration (USD Million), 2017-2021
5.    Global Phosphodiesterase (PDE) Inhibitors Market Forecast: Breakup by Route of Administration (USD Million), 2022-2027
6.    Global Phosphodiesterase (PDE) Inhibitors Historical Market: Breakup by Application (USD Million), 2017-2021
7.    Global Phosphodiesterase (PDE) Inhibitors Market Forecast: Breakup by Application (USD Million), 2022-2027
8.    Global Phosphodiesterase (PDE) Inhibitors Historical Market: Breakup by Region (USD Million), 2017-2021
9.    Global Phosphodiesterase (PDE) Inhibitors Market Forecast: Breakup by Region (USD Million), 2022-2027
10.    North America Phosphodiesterase (PDE) Inhibitors Historical Market: Breakup by Country (USD Million), 2017-2021
11.    North America Phosphodiesterase (PDE) Inhibitors Market Forecast: Breakup by Country (USD Million), 2022-2027
12.    Europe Phosphodiesterase (PDE) Inhibitors Historical Market: Breakup by Country (USD Million), 2017-2021
13.    Europe Phosphodiesterase (PDE) Inhibitors Market Forecast: Breakup by Country (USD Million), 2022-2027
14.    Asia Pacific Phosphodiesterase (PDE) Inhibitors Historical Market: Breakup by Country (USD Million), 2017-2021
15.    Asia Pacific Phosphodiesterase (PDE) Inhibitors Market Forecast: Breakup by Country (USD Million), 2022-2027
16.    Latin America Phosphodiesterase (PDE) Inhibitors Historical Market: Breakup by Country (USD Million), 2017-2021
17.    Latin America Phosphodiesterase (PDE) Inhibitors Market Forecast: Breakup by Country (USD Million), 2022-2027
18.    Middle East and Africa Phosphodiesterase (PDE) Inhibitors Historical Market: Breakup by Country (USD Million), 2017-2021
19.    Middle East and Africa Phosphodiesterase (PDE) Inhibitors Market Forecast: Breakup by Country (USD Million), 2022-2027
20.    Global Phosphodiesterase (PDE) Inhibitors Market Structure

Key Questions Answered in the Report

The global phosphodiesterase (PDE) inhibitors market is projected to grow at a CAGR of 5.4% between 2021 and 2026.

The major drivers of the industry, such as the increasing population, increasing health awareness, growing incidences of erectile dysfunction (ED), increasing preference for targeted therapy, growing demand for PDE5 inhibitors, and rapid technological advancements, are expected to aid the market growth.

The launch of new and improved PDE inhibitor variants is the key market trend guiding the growth of the industry.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

PDE4 and PDE5 inhibitors are the leading types of phosphodiesterase (PDE) inhibitors in the industry.

Oral and tropical, among others, are the significant routes of administration available for phosphodiesterase (PDE) inhibitors in the market.

The leading applications of the product include erectile dysfunction and chronic obstructive pulmonary disease, among others.

The major players in the industry are Bayer AG, Eli Lilly and Co., Pfizer Inc., Vivus Inc., and GlaxoSmithKline plc, among others.

Analyst Review

The global phosphodiesterase (PDE) inhibitors market is being driven by the growing cases of erectile dysfunction (ED) and advancements in technology. Aided by the increased investment in the development of new PDE inhibitors, the market is expected to witness a healthy growth in the forecast period of 2022-2027, growing at a CAGR of 5.4%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on types, the phosphodiesterase (PDE) inhibitors industry can be segmented into PDE4 and PDE5 inhibitors, among others. On the basis of route of administration, the industry is categorised into oral and tropical segments, among others. By application, the industry is bifurcated into erectile dysfunction and chronic obstructive pulmonary disease, among others. The major regional markets for phosphodiesterase (PDE) inhibitors are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., Vivus Inc., and others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER